Fig. 5: ZIC4 mediate the effects of DZNep on tumor promotion in vivo.
From: Epigenetic silencing of ZIC4 contributes to cancer progression in hepatocellular carcinoma
The HCC Xenograft transplantation mice models were built with HepG2 with or without ZIC4 knock down. 1 week after bearing, DZNep (1 mg/Kg) was administered intraperitoneally twice per week and every 2 weeks. A The representative image of xenograft tumors that developed in nude mice injected subcutaneously with sh-NC or sh-HepG2 stable cells (n = 5). B, C Tumor growth curve and quantification of weight of the solid tumor after indicated treatment (n = 5). D Representative picture of HE staining for solid tumor (n = 5). E Representative picture of Ki-67 IHC staining for solid tumor (n = 5). F Representative picture of EZH2, ZIC4, E-cadherin, and N-cadherin IHC staining for solid tumor (n = 5). *P < 0.05 vs. sh-NC mice without DZNep treatment, #P < 0.05 vs. sh-ZIC4 mice with DZNep treatment.
